Biomarker ID | 1655 |
PMID | 30958910 |
Year | 2019 |
Biomarker | miRâ€28; miRâ€100; miRâ€942; miRâ€28â€3p |
Biomarker Basis | Expression Based |
Biomolecule | miRNA |
Source | Plasma |
Subjects | Humans |
Regulation | NA |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | NA |
Experiment | Low Grade Vs High Grade Prostate Cancer |
Type of Biomarker | Prognostic |
Cohort | There were 66 men, aged 46â€86 years, included: 40 men with low-grade and 26 men with high-grade prostate cancers. |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | miRâ€28: p=0.016; miRâ€100: p=0.025; miRâ€942: p=0.025; miRâ€28â€3p: p=0.038 |
Method Used | NA |
Clinical | No |
Remarks | Low-Grade meant (Gleason score, 6 or 7 [3 + 4] and serum prostateâ€specific antigen [PSA], <20 ng/mL) and high-Grade meant (Gleason score, ≥7 (4 + 3) and serum PSA, ≥20 ng/mL) |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | NA |